How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Biological Heart Valve Market
- By Product Type: Porcine Heart Valves, Bovine Pericardial Heart Valves, Equine Heart Valves, Human (Homograft) Heart Valves, Stentless Biological Heart Valves
- By Valve Position: Aortic Valve, Mitral Valve, Pulmonary Valve, Tricuspid Valve
- By End User: Hospitals, Cardiac Surgery Centers, Ambulatory Surgical Centers
- By Valve Design: Stented Biological Valves, Stentless Biological Valves, Sutureless Biological Valves
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Porcine Heart Valves leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.162 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.170 →
Full report · locked preview
Everything inside the Biological Heart Valve Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Valve Position 4
End User 3
Valve Design 3
Companies profiled
Edwards Lifesciences Corporation
Medtronic plc
Abbott Laboratories
Boston Scientific Corporation
LivaNova PLC
CryoLife Inc.
Terumo Corporation
Sorin Group (now part of LivaNova)
Shanghai MicroPort Medical (Group) Co. Ltd.
JenaValve Technology Inc.
Braile Biomédica
Meril Life Sciences Pvt. Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Edwards Lifesciences Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →LivaNova PLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →CryoLife Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sorin Group (now part of LivaNova)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Shanghai MicroPort Medical (Group) Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →JenaValve Technology Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Braile Biomédica
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Meril Life Sciences Pvt. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →NVT AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Corcym S.p.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →ValveXchange
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$6,990M by 2033 · 11.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Porcine Heart Valves54.3
- Bovine Pericardial Heart Valves16.2
- Equine Heart Valves9.5
- Human (Homograft) Heart Valves13.3
- Stentless Biological Heart Valves6.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$998.1M → $2,200M · 10.4%
Europe$695.7M → $1,589M · 10.9%
Asia Pacific$635.2M → $1,448M · 10.9%
Latin America$393.2M → $945.5M · 11.6%
Middle East and Africa$302.5M → $708.5M · 11.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.992026
11.012027
11.012028
11.022029
11.032030
11.042031
11.072032
11.072033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Edwards Lifesciences Corporation14.7
- Medtronic plc20.2
- Abbott Laboratories9.0
- Boston Scientific Corporation11.5
- LivaNova PLC11.9
- CryoLife Inc.4.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type23.0%
Valve Position31.5%
End User17.4%
Valve Design28.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.9
- Europe23.1
- Asia Pacific21.0
- Latin America13.7
- Middle East and Africa10.3
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | 86 | 89 | 91 | 94 | 76 | 78 | 86 |
| Medtronic plc | 84 | 87 | 83 | 82 | 93 | 71 | 83 |
| Abbott Laboratories | 76 | 79 | 82 | 81 | 77 | 62 | 76 |
| Boston Scientific Corporation | 60 | 71 | 74 | 73 | 75 | 61 | 69 |
| LivaNova PLC | 72 | 64 | 66 | 64 | 68 | 70 | 67 |
| CryoLife Inc. | 63 | 67 | 48 | 57 | 59 | 63 | 60 |
| Terumo Corporation | 56 | 58 | 40 | 43 | 45 | 54 | 49 |
| Sorin Group (now part of LivaNova) | 48 | 50 | 49 | 35 | 38 | 40 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Edwards Lifesciences Corporation
- Medtronic plc
- Abbott Laboratories
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Medtronic plc | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Abbott Laboratories | ◐ | ◐ | ✓ | ✓ | ✓ | − |
| Boston Scientific Corporation | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| LivaNova PLC | − | ◐ | ◐ | ◐ | − | − |
| CryoLife Inc. | ◐ | ✓ | − | − | − | ◐ |
| Terumo Corporation | − | − | − | − | − | − |
| Sorin Group (now part of LivaNova) | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Edwards Lifesciences Corporation86
2Medtronic plc83
3Abbott Laboratories76
4Boston Scientific Corporation69
5LivaNova PLC67
6CryoLife Inc.60
7Terumo Corporation49
8Sorin Group (now part of LivaNova)43
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Edwards Lifesciences CorporationMedtronic plc
Challenger3
Strong scale, closing on the leaders.
Abbott LaboratoriesBoston Scientific CorporationLivaNova PLC
Contender1
Focused players with pockets of strength.
CryoLife Inc.
Niche2
Specialists in a single segment or region.
Terumo CorporationSorin Group (now part of LivaNova)
Go-to-market strategy
Land Product Type in North America, then scale across Biological Heart Valve Market — a $502M beachhead inside a $7.62B market.
Beachhead (SOM)$502Mobtainable near-term
Serviceable (SAM)$2.68Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Porcine Heart Valves
Best fit — highest urgency & budget in Product Type.
Economic buyer79 fit
Bovine Pericardial Heart Valves
Strong fit — clear ROI and a fast path to value.
End user66 fit
Equine Heart Valves
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Valve Position & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Biological Heart Valve Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified23%
Evaluation12%
Closed-won7%
$19.3KCAC
$115KLTV
6.0:1LTV : CAC
< 3 moCAC payback
Investment thesis
Biological Heart Valve Market is a resilient opportunity — $6.34B by 2033, compounding at 5.9%.
TAM · 2025$4.00Btoday
TAM · 2033$6.34Bforecast
CAGR5.9%2027–2033
Cumulative$45.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.34BTotal addressable market
SAM$2.61BServiceable available market
SOM$491MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.9% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.34BLarge & growingTAM by 2033 at 5.9% CAGR
$2.61BServiceable nowreachable with today’s model
$491MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.95BBear3.8% CAGR
$6.34BBase5.9% CAGR
$8.12BBull7.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Valve Position optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Biological Heart Valve Market — a $7.87B market by 2033. Plan: grow share from 6.7% to 13.2%.
Market size · 2033$7.87Btotal addressable
Market CAGR4.5%2027–2033
Target share13.2%from 6.7% today
Revenue ambition$1.04Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.7% | 13.2% | Behind |
| Revenue | $549M | $1.04B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 36.1% | 43.2% | At risk |
| Customer retention | 87.9% | 94.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Valve Position capability
A defensible second engine — invest in Valve Position to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Valve Position
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $113M capacity & capability investment
- Greenlight bolt-on M&A in Valve Position
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentAt risk
Sales deck · value proposition
Win the Biological Heart Valve Market conversation — a $1.44B market you can size, segment and defend in minutes.
Market size · 2033$1.44Btotal opportunity
Growth7.8%CAGR to 2033
Addressable buyers1,715+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 3 mopayback period
$66K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Edwards Lifesciences CorporationMedtronic plcAbbott LaboratoriesBoston Scientific CorporationLivaNova PLCCryoLife Inc.Terumo CorporationSorin Group (now part of LivaNova)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Biological Heart Valve Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Biological Heart Valve Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Biological Heart Valves Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportBiological Ice Bag Market
Market size, share, segmentation and regional forecast.
$477M market · 2025 base year
View reportBiological Indicator Incubator Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportBiological Indicator Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportBiological Integrated Circuit Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportBiological Microscope Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBiological Naphtha Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBiological Nerve Chip Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportBiological Oxygen Demand (Bod) Analyzers Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportBiological Particles Machine Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportBiological Pesticide(Biopestcides) Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportBiological Recognition Systems Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.